Clinical Trial Update: Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003) [Phase 1]

View source ↗

Summary

Phase 1 trial update on safety and immunogenicity of CMV vaccine V160 in healthy Japanese men completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• V160 (human cytomegalovirus vaccine V160)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Cytomegalovirus Infections | Phase 1 | Status: COMPLETED | Results posted: 2021-11-15